Review



sars-cov-2 cpass surrogate virus neutralization test (svnt) kit  (GenScript corporation)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GenScript corporation sars-cov-2 cpass surrogate virus neutralization test (svnt) kit
    Antibody titers from the first and second blood samples by the participants’ demographics.
    Sars Cov 2 Cpass Surrogate Virus Neutralization Test (Svnt) Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov-2+cpass+surrogate+virus+neutralization+test+(svnt)/cpass+sars+cov+2+neutralization+antibody+detection+kit/pmc11862019-86-6-14
    Average 90 stars, based on 1 article reviews
    sars-cov-2 cpass surrogate virus neutralization test (svnt) kit - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients"

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients

    Journal: Vaccines

    doi: 10.3390/vaccines13020170

    Antibody titers from the first and second blood samples by the participants’ demographics.
    Figure Legend Snippet: Antibody titers from the first and second blood samples by the participants’ demographics.

    Techniques Used: Infection, Sampling

    Locally estimated scatterplot smoothing curve based on data from the first blood sample collection, illustrating the relationship of antibody levels as follows: ( A – C ) inhibition rates (%) for the surrogate virus neutralization test (sVNT) against the wild-type (WT) strain, ( D – F ) inhibition rates (%) against the Omicron variant, and ( G – I ) IgG levels. The curves are plotted against the number of days since COVID-19 infection ( A , D , G ), the last vaccination ( B , E , H ), and the last exposure to COVID-19 ( C , F , I ). The blue line represents the regression line, and the shaded gray area indicates the 95% confidence interval.
    Figure Legend Snippet: Locally estimated scatterplot smoothing curve based on data from the first blood sample collection, illustrating the relationship of antibody levels as follows: ( A – C ) inhibition rates (%) for the surrogate virus neutralization test (sVNT) against the wild-type (WT) strain, ( D – F ) inhibition rates (%) against the Omicron variant, and ( G – I ) IgG levels. The curves are plotted against the number of days since COVID-19 infection ( A , D , G ), the last vaccination ( B , E , H ), and the last exposure to COVID-19 ( C , F , I ). The blue line represents the regression line, and the shaded gray area indicates the 95% confidence interval.

    Techniques Used: Inhibition, Virus, Neutralization, Variant Assay, Infection

    Locally estimated scatterplot smoothing curve based on data from the second blood sample collection, illustrating the relationship of antibody levels as follows: ( A – C ) inhibition rates (%) for the surrogate virus neutralization test (sVNT) against the wild-type (WT) strain, ( D – F ) inhibition rates (%) against the Omicron variant, and ( G – I ) IgG levels. The curves are plotted against the number of days since COVID-19 infection ( A , D , G ), the last vaccination ( B , E , H ), and the last exposure to COVID-19 ( C , F , I ). The blue line represents the regression line, and the shaded gray area indicates the 95% confidence interval.
    Figure Legend Snippet: Locally estimated scatterplot smoothing curve based on data from the second blood sample collection, illustrating the relationship of antibody levels as follows: ( A – C ) inhibition rates (%) for the surrogate virus neutralization test (sVNT) against the wild-type (WT) strain, ( D – F ) inhibition rates (%) against the Omicron variant, and ( G – I ) IgG levels. The curves are plotted against the number of days since COVID-19 infection ( A , D , G ), the last vaccination ( B , E , H ), and the last exposure to COVID-19 ( C , F , I ). The blue line represents the regression line, and the shaded gray area indicates the 95% confidence interval.

    Techniques Used: Inhibition, Virus, Neutralization, Variant Assay, Infection

    Related Articles

    Virus:

    Article Title: Comparative Study on the Immunogenicity of COVID-19 mRNA Vaccines in Patients Receiving Adjuvant and Palliative Chemotherapy
    Article Snippet: The SARS-CoV-2 cPass Surrogate Virus Neutralization Test (sVNT) (Genscript Biotech Co., NJ, USA) was performed using a ThunderBolt ELISA Analyzer (Gold Standard Diagnostics, CA, USA).

    Article Title: Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan
    Article Snippet: In this study, we utilized our previously reported results of serological testing for antibodies against the receptor-binding domain (RBD) of the S1 subunit of the viral spike protein [IgG(S-RBD)], IgG(N), and surrogate virus neutralization test (sVNT; cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript Biotech Corporation, Piscataway, NJ, USA) [ ] to investigate the correlation between the spike-specific PBMC responses tested in this study and the humoral immune responses demonstrated in our prior interim report [ ].

    Article Title: Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan
    Article Snippet: A commercially available surrogate virus neutralization test (sVNT; cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript Biotech Corporation, Piscataway, NJ, USA) was used.

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients
    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spike-specific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Article Title: Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection.
    Article Snippet: Assessment of neutralizing antibody responses against SARS-CoV-2 Neutralizing antibody responses against wild type SARS-CoV-2 were detected using the GenScript SARS-CoV-2 cPass surrogate virus neutralization test (SVNT-WT) kit (GenScript Biotech Corporation, Piscataway, NJ, USA).

    Article Title: SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost.
    Article Snippet: The aim of this study was to evaluate immunogenicity and longevity of the humoral immune response within six months after the homologous (BNT162b2/BNT162b2) or heterologous (BBIBP-CorV/BNT162b2) third dose, and to assess breakthrough infections among vaccinees during the Omicron wave in Serbia.. Serum samples were analyzed at four timepoints: five months after the primary series; three weeks, three months, and six months after the boost.. IgG antibodies against the receptor-binding domain of the spike protein were detected using enzymelinked fluorescence assay.

    Article Title: Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
    Article Snippet: Neutralizing antibody responses against wild type SARS-CoV-2 were detected using the GenScript SARS-CoV-2 cPass surrogate virus neutralization test (SVNT-WT) kit (GenScript Biotech Corporation, Piscataway, NJ, USA).

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients.
    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spikespecific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Neutralization:

    Article Title: Comparative Study on the Immunogenicity of COVID-19 mRNA Vaccines in Patients Receiving Adjuvant and Palliative Chemotherapy
    Article Snippet: The SARS-CoV-2 cPass Surrogate Virus Neutralization Test (sVNT) (Genscript Biotech Co., NJ, USA) was performed using a ThunderBolt ELISA Analyzer (Gold Standard Diagnostics, CA, USA).

    Article Title: Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan
    Article Snippet: In this study, we utilized our previously reported results of serological testing for antibodies against the receptor-binding domain (RBD) of the S1 subunit of the viral spike protein [IgG(S-RBD)], IgG(N), and surrogate virus neutralization test (sVNT; cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript Biotech Corporation, Piscataway, NJ, USA) [ ] to investigate the correlation between the spike-specific PBMC responses tested in this study and the humoral immune responses demonstrated in our prior interim report [ ].

    Article Title: Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan
    Article Snippet: A commercially available surrogate virus neutralization test (sVNT; cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript Biotech Corporation, Piscataway, NJ, USA) was used.

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients
    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spike-specific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Article Title: Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection.
    Article Snippet: Assessment of neutralizing antibody responses against SARS-CoV-2 Neutralizing antibody responses against wild type SARS-CoV-2 were detected using the GenScript SARS-CoV-2 cPass surrogate virus neutralization test (SVNT-WT) kit (GenScript Biotech Corporation, Piscataway, NJ, USA).

    Article Title: SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost.
    Article Snippet: The aim of this study was to evaluate immunogenicity and longevity of the humoral immune response within six months after the homologous (BNT162b2/BNT162b2) or heterologous (BBIBP-CorV/BNT162b2) third dose, and to assess breakthrough infections among vaccinees during the Omicron wave in Serbia.. Serum samples were analyzed at four timepoints: five months after the primary series; three weeks, three months, and six months after the boost.. IgG antibodies against the receptor-binding domain of the spike protein were detected using enzymelinked fluorescence assay.

    Article Title: Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
    Article Snippet: Neutralizing antibody responses against wild type SARS-CoV-2 were detected using the GenScript SARS-CoV-2 cPass surrogate virus neutralization test (SVNT-WT) kit (GenScript Biotech Corporation, Piscataway, NJ, USA).

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients.
    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spikespecific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Enzyme-linked Immunosorbent Assay:

    Article Title: Comparative Study on the Immunogenicity of COVID-19 mRNA Vaccines in Patients Receiving Adjuvant and Palliative Chemotherapy
    Article Snippet: The SARS-CoV-2 cPass Surrogate Virus Neutralization Test (sVNT) (Genscript Biotech Co., NJ, USA) was performed using a ThunderBolt ELISA Analyzer (Gold Standard Diagnostics, CA, USA).

    Article Title: Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan
    Article Snippet: In this study, we utilized our previously reported results of serological testing for antibodies against the receptor-binding domain (RBD) of the S1 subunit of the viral spike protein [IgG(S-RBD)], IgG(N), and surrogate virus neutralization test (sVNT; cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript Biotech Corporation, Piscataway, NJ, USA) [ ] to investigate the correlation between the spike-specific PBMC responses tested in this study and the humoral immune responses demonstrated in our prior interim report [ ].

    Article Title: Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan
    Article Snippet: A commercially available surrogate virus neutralization test (sVNT; cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript Biotech Corporation, Piscataway, NJ, USA) was used.

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients
    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spike-specific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Article Title: Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection.
    Article Snippet: Assessment of neutralizing antibody responses against SARS-CoV-2 Neutralizing antibody responses against wild type SARS-CoV-2 were detected using the GenScript SARS-CoV-2 cPass surrogate virus neutralization test (SVNT-WT) kit (GenScript Biotech Corporation, Piscataway, NJ, USA).

    Article Title: SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost.
    Article Snippet: The aim of this study was to evaluate immunogenicity and longevity of the humoral immune response within six months after the homologous (BNT162b2/BNT162b2) or heterologous (BBIBP-CorV/BNT162b2) third dose, and to assess breakthrough infections among vaccinees during the Omicron wave in Serbia.. Serum samples were analyzed at four timepoints: five months after the primary series; three weeks, three months, and six months after the boost.. IgG antibodies against the receptor-binding domain of the spike protein were detected using enzymelinked fluorescence assay.

    Article Title: Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
    Article Snippet: Neutralizing antibody responses against wild type SARS-CoV-2 were detected using the GenScript SARS-CoV-2 cPass surrogate virus neutralization test (SVNT-WT) kit (GenScript Biotech Corporation, Piscataway, NJ, USA).

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients.
    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spikespecific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Infection:

    Article Title: Comparative Study on the Immunogenicity of COVID-19 mRNA Vaccines in Patients Receiving Adjuvant and Palliative Chemotherapy
    Article Snippet: The SARS-CoV-2 cPass Surrogate Virus Neutralization Test (sVNT) (Genscript Biotech Co., NJ, USA) was performed using a ThunderBolt ELISA Analyzer (Gold Standard Diagnostics, CA, USA).

    Article Title: Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan
    Article Snippet: In this study, we utilized our previously reported results of serological testing for antibodies against the receptor-binding domain (RBD) of the S1 subunit of the viral spike protein [IgG(S-RBD)], IgG(N), and surrogate virus neutralization test (sVNT; cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript Biotech Corporation, Piscataway, NJ, USA) [ ] to investigate the correlation between the spike-specific PBMC responses tested in this study and the humoral immune responses demonstrated in our prior interim report [ ].

    Article Title: Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan
    Article Snippet: A commercially available surrogate virus neutralization test (sVNT; cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript Biotech Corporation, Piscataway, NJ, USA) was used.

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients
    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spike-specific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Article Title: Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection.
    Article Snippet: Assessment of neutralizing antibody responses against SARS-CoV-2 Neutralizing antibody responses against wild type SARS-CoV-2 were detected using the GenScript SARS-CoV-2 cPass surrogate virus neutralization test (SVNT-WT) kit (GenScript Biotech Corporation, Piscataway, NJ, USA).

    Article Title: SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost.
    Article Snippet: The aim of this study was to evaluate immunogenicity and longevity of the humoral immune response within six months after the homologous (BNT162b2/BNT162b2) or heterologous (BBIBP-CorV/BNT162b2) third dose, and to assess breakthrough infections among vaccinees during the Omicron wave in Serbia.. Serum samples were analyzed at four timepoints: five months after the primary series; three weeks, three months, and six months after the boost.. IgG antibodies against the receptor-binding domain of the spike protein were detected using enzymelinked fluorescence assay.

    Article Title: Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
    Article Snippet: Neutralizing antibody responses against wild type SARS-CoV-2 were detected using the GenScript SARS-CoV-2 cPass surrogate virus neutralization test (SVNT-WT) kit (GenScript Biotech Corporation, Piscataway, NJ, USA).

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients.
    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spikespecific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Sampling:

    Article Title: Comparative Study on the Immunogenicity of COVID-19 mRNA Vaccines in Patients Receiving Adjuvant and Palliative Chemotherapy
    Article Snippet: The SARS-CoV-2 cPass Surrogate Virus Neutralization Test (sVNT) (Genscript Biotech Co., NJ, USA) was performed using a ThunderBolt ELISA Analyzer (Gold Standard Diagnostics, CA, USA).

    Article Title: Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan
    Article Snippet: In this study, we utilized our previously reported results of serological testing for antibodies against the receptor-binding domain (RBD) of the S1 subunit of the viral spike protein [IgG(S-RBD)], IgG(N), and surrogate virus neutralization test (sVNT; cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript Biotech Corporation, Piscataway, NJ, USA) [ ] to investigate the correlation between the spike-specific PBMC responses tested in this study and the humoral immune responses demonstrated in our prior interim report [ ].

    Article Title: Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan
    Article Snippet: A commercially available surrogate virus neutralization test (sVNT; cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript Biotech Corporation, Piscataway, NJ, USA) was used.

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients
    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spike-specific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Article Title: Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection.
    Article Snippet: Assessment of neutralizing antibody responses against SARS-CoV-2 Neutralizing antibody responses against wild type SARS-CoV-2 were detected using the GenScript SARS-CoV-2 cPass surrogate virus neutralization test (SVNT-WT) kit (GenScript Biotech Corporation, Piscataway, NJ, USA).

    Article Title: SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost.
    Article Snippet: The aim of this study was to evaluate immunogenicity and longevity of the humoral immune response within six months after the homologous (BNT162b2/BNT162b2) or heterologous (BBIBP-CorV/BNT162b2) third dose, and to assess breakthrough infections among vaccinees during the Omicron wave in Serbia.. Serum samples were analyzed at four timepoints: five months after the primary series; three weeks, three months, and six months after the boost.. IgG antibodies against the receptor-binding domain of the spike protein were detected using enzymelinked fluorescence assay.

    Article Title: Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
    Article Snippet: Neutralizing antibody responses against wild type SARS-CoV-2 were detected using the GenScript SARS-CoV-2 cPass surrogate virus neutralization test (SVNT-WT) kit (GenScript Biotech Corporation, Piscataway, NJ, USA).

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients.
    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spikespecific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Inhibition:

    Article Title: Comparative Study on the Immunogenicity of COVID-19 mRNA Vaccines in Patients Receiving Adjuvant and Palliative Chemotherapy
    Article Snippet: The SARS-CoV-2 cPass Surrogate Virus Neutralization Test (sVNT) (Genscript Biotech Co., NJ, USA) was performed using a ThunderBolt ELISA Analyzer (Gold Standard Diagnostics, CA, USA).

    Article Title: Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan
    Article Snippet: In this study, we utilized our previously reported results of serological testing for antibodies against the receptor-binding domain (RBD) of the S1 subunit of the viral spike protein [IgG(S-RBD)], IgG(N), and surrogate virus neutralization test (sVNT; cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript Biotech Corporation, Piscataway, NJ, USA) [ ] to investigate the correlation between the spike-specific PBMC responses tested in this study and the humoral immune responses demonstrated in our prior interim report [ ].

    Article Title: Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan
    Article Snippet: A commercially available surrogate virus neutralization test (sVNT; cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript Biotech Corporation, Piscataway, NJ, USA) was used.

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients
    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spike-specific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Article Title: Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection.
    Article Snippet: Assessment of neutralizing antibody responses against SARS-CoV-2 Neutralizing antibody responses against wild type SARS-CoV-2 were detected using the GenScript SARS-CoV-2 cPass surrogate virus neutralization test (SVNT-WT) kit (GenScript Biotech Corporation, Piscataway, NJ, USA).

    Article Title: SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost.
    Article Snippet: The aim of this study was to evaluate immunogenicity and longevity of the humoral immune response within six months after the homologous (BNT162b2/BNT162b2) or heterologous (BBIBP-CorV/BNT162b2) third dose, and to assess breakthrough infections among vaccinees during the Omicron wave in Serbia.. Serum samples were analyzed at four timepoints: five months after the primary series; three weeks, three months, and six months after the boost.. IgG antibodies against the receptor-binding domain of the spike protein were detected using enzymelinked fluorescence assay.

    Article Title: Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
    Article Snippet: Neutralizing antibody responses against wild type SARS-CoV-2 were detected using the GenScript SARS-CoV-2 cPass surrogate virus neutralization test (SVNT-WT) kit (GenScript Biotech Corporation, Piscataway, NJ, USA).

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients.
    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spikespecific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Variant Assay:

    Article Title: Comparative Study on the Immunogenicity of COVID-19 mRNA Vaccines in Patients Receiving Adjuvant and Palliative Chemotherapy
    Article Snippet: The SARS-CoV-2 cPass Surrogate Virus Neutralization Test (sVNT) (Genscript Biotech Co., NJ, USA) was performed using a ThunderBolt ELISA Analyzer (Gold Standard Diagnostics, CA, USA).

    Article Title: Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan
    Article Snippet: In this study, we utilized our previously reported results of serological testing for antibodies against the receptor-binding domain (RBD) of the S1 subunit of the viral spike protein [IgG(S-RBD)], IgG(N), and surrogate virus neutralization test (sVNT; cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript Biotech Corporation, Piscataway, NJ, USA) [ ] to investigate the correlation between the spike-specific PBMC responses tested in this study and the humoral immune responses demonstrated in our prior interim report [ ].

    Article Title: Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan
    Article Snippet: A commercially available surrogate virus neutralization test (sVNT; cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript Biotech Corporation, Piscataway, NJ, USA) was used.

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients
    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spike-specific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Article Title: Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection.
    Article Snippet: Assessment of neutralizing antibody responses against SARS-CoV-2 Neutralizing antibody responses against wild type SARS-CoV-2 were detected using the GenScript SARS-CoV-2 cPass surrogate virus neutralization test (SVNT-WT) kit (GenScript Biotech Corporation, Piscataway, NJ, USA).

    Article Title: SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost.
    Article Snippet: The aim of this study was to evaluate immunogenicity and longevity of the humoral immune response within six months after the homologous (BNT162b2/BNT162b2) or heterologous (BBIBP-CorV/BNT162b2) third dose, and to assess breakthrough infections among vaccinees during the Omicron wave in Serbia.. Serum samples were analyzed at four timepoints: five months after the primary series; three weeks, three months, and six months after the boost.. IgG antibodies against the receptor-binding domain of the spike protein were detected using enzymelinked fluorescence assay.

    Article Title: Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
    Article Snippet: Neutralizing antibody responses against wild type SARS-CoV-2 were detected using the GenScript SARS-CoV-2 cPass surrogate virus neutralization test (SVNT-WT) kit (GenScript Biotech Corporation, Piscataway, NJ, USA).

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients.
    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spikespecific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Release Assay:

    Article Title: Comparative Study on the Immunogenicity of COVID-19 mRNA Vaccines in Patients Receiving Adjuvant and Palliative Chemotherapy
    Article Snippet: The SARS-CoV-2 cPass Surrogate Virus Neutralization Test (sVNT) (Genscript Biotech Co., NJ, USA) was performed using a ThunderBolt ELISA Analyzer (Gold Standard Diagnostics, CA, USA).

    Article Title: Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan
    Article Snippet: In this study, we utilized our previously reported results of serological testing for antibodies against the receptor-binding domain (RBD) of the S1 subunit of the viral spike protein [IgG(S-RBD)], IgG(N), and surrogate virus neutralization test (sVNT; cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript Biotech Corporation, Piscataway, NJ, USA) [ ] to investigate the correlation between the spike-specific PBMC responses tested in this study and the humoral immune responses demonstrated in our prior interim report [ ].

    Article Title: Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan
    Article Snippet: A commercially available surrogate virus neutralization test (sVNT; cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript Biotech Corporation, Piscataway, NJ, USA) was used.

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients
    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spike-specific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Article Title: Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection.
    Article Snippet: Assessment of neutralizing antibody responses against SARS-CoV-2 Neutralizing antibody responses against wild type SARS-CoV-2 were detected using the GenScript SARS-CoV-2 cPass surrogate virus neutralization test (SVNT-WT) kit (GenScript Biotech Corporation, Piscataway, NJ, USA).

    Article Title: SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost.
    Article Snippet: The aim of this study was to evaluate immunogenicity and longevity of the humoral immune response within six months after the homologous (BNT162b2/BNT162b2) or heterologous (BBIBP-CorV/BNT162b2) third dose, and to assess breakthrough infections among vaccinees during the Omicron wave in Serbia.. Serum samples were analyzed at four timepoints: five months after the primary series; three weeks, three months, and six months after the boost.. IgG antibodies against the receptor-binding domain of the spike protein were detected using enzymelinked fluorescence assay.

    Article Title: Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
    Article Snippet: Neutralizing antibody responses against wild type SARS-CoV-2 were detected using the GenScript SARS-CoV-2 cPass surrogate virus neutralization test (SVNT-WT) kit (GenScript Biotech Corporation, Piscataway, NJ, USA).

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients.
    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spikespecific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Comparison:

    Article Title: Comparative Study on the Immunogenicity of COVID-19 mRNA Vaccines in Patients Receiving Adjuvant and Palliative Chemotherapy
    Article Snippet: The SARS-CoV-2 cPass Surrogate Virus Neutralization Test (sVNT) (Genscript Biotech Co., NJ, USA) was performed using a ThunderBolt ELISA Analyzer (Gold Standard Diagnostics, CA, USA).

    Article Title: Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan
    Article Snippet: In this study, we utilized our previously reported results of serological testing for antibodies against the receptor-binding domain (RBD) of the S1 subunit of the viral spike protein [IgG(S-RBD)], IgG(N), and surrogate virus neutralization test (sVNT; cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript Biotech Corporation, Piscataway, NJ, USA) [ ] to investigate the correlation between the spike-specific PBMC responses tested in this study and the humoral immune responses demonstrated in our prior interim report [ ].

    Article Title: Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan
    Article Snippet: A commercially available surrogate virus neutralization test (sVNT; cPass SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript Biotech Corporation, Piscataway, NJ, USA) was used.

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients
    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spike-specific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Article Title: Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection.
    Article Snippet: Assessment of neutralizing antibody responses against SARS-CoV-2 Neutralizing antibody responses against wild type SARS-CoV-2 were detected using the GenScript SARS-CoV-2 cPass surrogate virus neutralization test (SVNT-WT) kit (GenScript Biotech Corporation, Piscataway, NJ, USA).

    Article Title: SARS-CoV-2 specific antibody response after an mRNA vaccine as the third dose: Homologous versus heterologous boost.
    Article Snippet: The aim of this study was to evaluate immunogenicity and longevity of the humoral immune response within six months after the homologous (BNT162b2/BNT162b2) or heterologous (BBIBP-CorV/BNT162b2) third dose, and to assess breakthrough infections among vaccinees during the Omicron wave in Serbia.. Serum samples were analyzed at four timepoints: five months after the primary series; three weeks, three months, and six months after the boost.. IgG antibodies against the receptor-binding domain of the spike protein were detected using enzymelinked fluorescence assay.

    Article Title: Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
    Article Snippet: Neutralizing antibody responses against wild type SARS-CoV-2 were detected using the GenScript SARS-CoV-2 cPass surrogate virus neutralization test (SVNT-WT) kit (GenScript Biotech Corporation, Piscataway, NJ, USA).

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients.
    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spikespecific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).



    Similar Products

    sars-cov-2 cpass surrogate virus neutralization test (svnt) kit  (GenScript corporation)
    90
    GenScript corporation sars-cov-2 cpass surrogate virus neutralization test (svnt) kit
    Antibody titers from the first and second blood samples by the participants’ demographics.
    Sars Cov 2 Cpass Surrogate Virus Neutralization Test (Svnt) Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov-2+cpass+surrogate+virus+neutralization+test+(svnt)/cpass+sars+cov+2+neutralization+antibody+detection+kit/pmc11862019-86-6-14
    Average 90 stars, based on 1 article reviews
    sars-cov-2 cpass surrogate virus neutralization test (svnt) kit - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    surrogate virus neutralization test (svnt) employing the cpass sars-cov-2 neutralization antibody detection kit  (GenScript corporation)
    90
    GenScript corporation surrogate virus neutralization test (svnt) employing the cpass sars-cov-2 neutralization antibody detection kit
    Antibody titers from the first and second blood samples by the participants’ demographics.
    Surrogate Virus Neutralization Test (Svnt) Employing The Cpass Sars Cov 2 Neutralization Antibody Detection Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov-2+cpass+surrogate+virus+neutralization+test+(svnt)/surrogate+virus+neutralization+test++svnt+/pmc11394176-85-19-25
    Average 90 stars, based on 1 article reviews
    surrogate virus neutralization test (svnt) employing the cpass sars-cov-2 neutralization antibody detection kit - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    cpass sars-cov-2 surrogate virus neutralization test (svnt)  (GenScript corporation)
    90
    GenScript corporation cpass sars-cov-2 surrogate virus neutralization test (svnt)
    Antibody titers from the first and second blood samples by the participants’ demographics.
    Cpass Sars Cov 2 Surrogate Virus Neutralization Test (Svnt), supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov-2+cpass+surrogate+virus+neutralization+test+(svnt)/cpass+sars+cov+2+neutralization+antibody+detection+kit/pmc10974415-95-1-8
    Average 90 stars, based on 1 article reviews
    cpass sars-cov-2 surrogate virus neutralization test (svnt) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    sars-cov-2 cpass surrogate virus neutralization test (svnt)  (GenScript corporation)
    90
    GenScript corporation sars-cov-2 cpass surrogate virus neutralization test (svnt)
    Antibody titers from the first and second blood samples by the participants’ demographics.
    Sars Cov 2 Cpass Surrogate Virus Neutralization Test (Svnt), supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov-2+cpass+surrogate+virus+neutralization+test+(svnt)/cpass+sars+cov+2+neutralization+antibody+detection+kit/pmc10828089-46-1-8
    Average 90 stars, based on 1 article reviews
    sars-cov-2 cpass surrogate virus neutralization test (svnt) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    sars-cov-2 cpass surrogate virus neutralization test (svnt-wt) kit  (GenScript corporation)
    90
    GenScript corporation sars-cov-2 cpass surrogate virus neutralization test (svnt-wt) kit
    Antibody titers from the first and second blood samples by the participants’ demographics.
    Sars Cov 2 Cpass Surrogate Virus Neutralization Test (Svnt Wt) Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov-2+cpass+surrogate+virus+neutralization+test+(svnt)/cpass+sars+cov+2+neutralization+antibody+detection+kit/pm37218354-52-19-27
    Average 90 stars, based on 1 article reviews
    sars-cov-2 cpass surrogate virus neutralization test (svnt-wt) kit - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    sars-cov-2 surrogate virus neutralization test (svnt) by genscript cpass tm sars-cov-2 neutralization antibody detection kit  (GenScript corporation)
    90
    GenScript corporation sars-cov-2 surrogate virus neutralization test (svnt) by genscript cpass tm sars-cov-2 neutralization antibody detection kit
    Antibody titers from the first and second blood samples by the participants’ demographics.
    Sars Cov 2 Surrogate Virus Neutralization Test (Svnt) By Genscript Cpass Tm Sars Cov 2 Neutralization Antibody Detection Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov-2+cpass+surrogate+virus+neutralization+test+(svnt)/cpass+sars+cov+2+neutralization+antibody+detection+kit/pm36693568-10-30-29
    Average 90 stars, based on 1 article reviews
    sars-cov-2 surrogate virus neutralization test (svnt) by genscript cpass tm sars-cov-2 neutralization antibody detection kit - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    sars-cov-2 surrogate virus neutralization test (svnt) kit (cpass™  (GenScript corporation)
    90
    GenScript corporation sars-cov-2 surrogate virus neutralization test (svnt) kit (cpass™
    Levels of anti-spike antibodies in sera of participants as determined using an in-house ELISA. Arbitrary units were calculated against the WHO international standard <t>anti-SARS-CoV-2</t> immunoglobulin. The dash line representing the cutoff was calculated from the mean arbitrary units of the control group plus 2 standard deviations (54.28). Each symbol represents one individual. The vertical lines and error bars indicate the median and interquartile range. The p values were calculated from the post hoc comparisons using the Kruskal–Wallis Test.
    Sars Cov 2 Surrogate Virus Neutralization Test (Svnt) Kit (Cpass™, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov-2+cpass+surrogate+virus+neutralization+test+(svnt)/cpass+sars+cov+2+neutralization+antibody+detection+kit/pmc10119672-58-0-11
    Average 90 stars, based on 1 article reviews
    sars-cov-2 surrogate virus neutralization test (svnt) kit (cpass™ - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    cpass™ sars-cov-2 surrogate virus neutralization test (svnt 50)  (GenScript corporation)
    90
    GenScript corporation cpass™ sars-cov-2 surrogate virus neutralization test (svnt 50)
    Levels of anti-spike antibodies in sera of participants as determined using an in-house ELISA. Arbitrary units were calculated against the WHO international standard <t>anti-SARS-CoV-2</t> immunoglobulin. The dash line representing the cutoff was calculated from the mean arbitrary units of the control group plus 2 standard deviations (54.28). Each symbol represents one individual. The vertical lines and error bars indicate the median and interquartile range. The p values were calculated from the post hoc comparisons using the Kruskal–Wallis Test.
    Cpass™ Sars Cov 2 Surrogate Virus Neutralization Test (Svnt 50), supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sars-cov-2+cpass+surrogate+virus+neutralization+test+(svnt)/cpass+sars+cov+2+neutralization+antibody+detection+kit/pmc10053821-64-19-29
    Average 90 stars, based on 1 article reviews
    cpass™ sars-cov-2 surrogate virus neutralization test (svnt 50) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Antibody titers from the first and second blood samples by the participants’ demographics.

    Journal: Vaccines

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients

    doi: 10.3390/vaccines13020170

    Figure Lengend Snippet: Antibody titers from the first and second blood samples by the participants’ demographics.

    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spike-specific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Techniques: Infection, Sampling

    Locally estimated scatterplot smoothing curve based on data from the first blood sample collection, illustrating the relationship of antibody levels as follows: ( A – C ) inhibition rates (%) for the surrogate virus neutralization test (sVNT) against the wild-type (WT) strain, ( D – F ) inhibition rates (%) against the Omicron variant, and ( G – I ) IgG levels. The curves are plotted against the number of days since COVID-19 infection ( A , D , G ), the last vaccination ( B , E , H ), and the last exposure to COVID-19 ( C , F , I ). The blue line represents the regression line, and the shaded gray area indicates the 95% confidence interval.

    Journal: Vaccines

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients

    doi: 10.3390/vaccines13020170

    Figure Lengend Snippet: Locally estimated scatterplot smoothing curve based on data from the first blood sample collection, illustrating the relationship of antibody levels as follows: ( A – C ) inhibition rates (%) for the surrogate virus neutralization test (sVNT) against the wild-type (WT) strain, ( D – F ) inhibition rates (%) against the Omicron variant, and ( G – I ) IgG levels. The curves are plotted against the number of days since COVID-19 infection ( A , D , G ), the last vaccination ( B , E , H ), and the last exposure to COVID-19 ( C , F , I ). The blue line represents the regression line, and the shaded gray area indicates the 95% confidence interval.

    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spike-specific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Techniques: Inhibition, Virus, Neutralization, Variant Assay, Infection

    Locally estimated scatterplot smoothing curve based on data from the second blood sample collection, illustrating the relationship of antibody levels as follows: ( A – C ) inhibition rates (%) for the surrogate virus neutralization test (sVNT) against the wild-type (WT) strain, ( D – F ) inhibition rates (%) against the Omicron variant, and ( G – I ) IgG levels. The curves are plotted against the number of days since COVID-19 infection ( A , D , G ), the last vaccination ( B , E , H ), and the last exposure to COVID-19 ( C , F , I ). The blue line represents the regression line, and the shaded gray area indicates the 95% confidence interval.

    Journal: Vaccines

    Article Title: The Humoral Immune Response Against COVID-19 Through Vaccination in Hemodialysis Patients

    doi: 10.3390/vaccines13020170

    Figure Lengend Snippet: Locally estimated scatterplot smoothing curve based on data from the second blood sample collection, illustrating the relationship of antibody levels as follows: ( A – C ) inhibition rates (%) for the surrogate virus neutralization test (sVNT) against the wild-type (WT) strain, ( D – F ) inhibition rates (%) against the Omicron variant, and ( G – I ) IgG levels. The curves are plotted against the number of days since COVID-19 infection ( A , D , G ), the last vaccination ( B , E , H ), and the last exposure to COVID-19 ( C , F , I ). The blue line represents the regression line, and the shaded gray area indicates the 95% confidence interval.

    Article Snippet: NAb was measured using the GenScript SARS-CoV-2 cPASS surrogate virus neutralization test (sVNT) kit (Genscript Biotech Corporation, Piscataway, NJ, USA) and spike-specific immunoglobulin G (IgG) was measured with the Euroimmun anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany).

    Techniques: Inhibition, Virus, Neutralization, Variant Assay, Infection

    Levels of anti-spike antibodies in sera of participants as determined using an in-house ELISA. Arbitrary units were calculated against the WHO international standard anti-SARS-CoV-2 immunoglobulin. The dash line representing the cutoff was calculated from the mean arbitrary units of the control group plus 2 standard deviations (54.28). Each symbol represents one individual. The vertical lines and error bars indicate the median and interquartile range. The p values were calculated from the post hoc comparisons using the Kruskal–Wallis Test.

    Journal: Vaccine: X

    Article Title: Comparison of antibody responses following natural infection with Severe Acute Respiratory Syndrome Coronavirus 2 or receipt of CoronaVac or ChAdOx1 (AZD1222) vaccination in Chiang Mai, Thailand

    doi: 10.1016/j.jvacx.2023.100305

    Figure Lengend Snippet: Levels of anti-spike antibodies in sera of participants as determined using an in-house ELISA. Arbitrary units were calculated against the WHO international standard anti-SARS-CoV-2 immunoglobulin. The dash line representing the cutoff was calculated from the mean arbitrary units of the control group plus 2 standard deviations (54.28). Each symbol represents one individual. The vertical lines and error bars indicate the median and interquartile range. The p values were calculated from the post hoc comparisons using the Kruskal–Wallis Test.

    Article Snippet: SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit (cPass™) was purchased from Genscript (Piscataway, USA).

    Techniques: Enzyme-linked Immunosorbent Assay